7-Nov-2024
No headlines found.
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Globe Newswire (Wed, 6-Nov 8:00 AM ET)
Globe Newswire (Tue, 5-Nov 4:05 PM ET)
Globe Newswire (Tue, 5-Nov 8:00 AM ET)
Globe Newswire (Mon, 4-Nov 8:00 AM ET)
Globe Newswire (Thu, 31-Oct 6:54 PM ET)
Globe Newswire (Wed, 23-Oct 9:00 AM ET)
Globe Newswire (Tue, 22-Oct 8:00 AM ET)
Globe Newswire (Wed, 16-Oct 4:35 PM ET)
PRNewswire (Wed, 16-Oct 4:34 PM ET)
Globe Newswire (Fri, 27-Sep 8:00 AM ET)
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.
As of November 7, 2024, LXRX stock price climbed to $1.30 with 4,189,375 million shares trading.
LXRX has a beta of 2.98, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.12 to the broad based SPY ETF.
LXRX has a market cap of $469.94 million. This is considered a Small Cap stock.
Last quarter Lexicon Pharmaceuticals reported $2 million in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.02.
In the last 3 years, LXRX traded as high as $5.28 and as low as $.92.
The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, IWM, SCHA, VTWO.
LXRX has underperformed the market in the last year with a price return of +4.0% while the SPY ETF gained +37.9%. LXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.7% and -29.3%, respectively, while the SPY returned +15.2% and +2.8%, respectively.
LXRX support price is $1.14 and resistance is $1.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.